We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Solid Biosciences Inc | NASDAQ:SLDB | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 7.72 | 3.11 | 12.35 | 0 | 09:09:54 |
From Dec 2023 to Jun 2024
By Dean Seal
Shares of Solid Biosciences rose after the company said regulators have granted their fast-track designation to its treatment for Duchenne muscular dystrophy.
The stock was up 16% at $3.98 in early trading. Shares are still down 26% year-to-date.
The life sciences company said Thursday that the U.S. Food and Drug Administration granted the designation for SGT-003, its gene therapy candidate for Duchenne muscular dystrophy.
The FDA's fast-track designation facilitates development and expedites the review of drugs that treat serious or life-threatening conditions and fill unmet medical needs.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
December 07, 2023 10:34 ET (15:34 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Solid Biosciences Chart |
1 Month Solid Biosciences Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
